TY - JOUR
AU - Völker, Lotta
AU - Müller-Jensen, Leonie
AU - Carl, Sophia
AU - Nay, Sandra
AU - Möllenkamp, Thiemo Malte
AU - Schultze-Florey, Christian
AU - Grote-Levi, Lea
AU - Jendretzky, Konstantin F
AU - Konen, Franz Felix
AU - Könecke, Christian
AU - Eder, Matthias
AU - Panagiota, Victoria
AU - Heidel, Florian H
AU - Bullinger, Lars
AU - Damm, Frederik
AU - Frick, Mareike
AU - Penack, Olaf
AU - Ludwig, Rebecca
AU - Buß, Eric Anil
AU - Boehmerle, Wolfgang
AU - Endres, Matthias
AU - Gudi, Viktoria
AU - Huehnchen, Petra
AU - Skripuletz, Thomas
AU - Möhn, Nora
TI - The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.
JO - Frontiers in neurology
VL - 17
SN - 1664-2295
CY - Lausanne
PB - Frontiers Research Foundation
M1 - DZNE-2026-00176
SP - 1726779
PY - 2026
AB - Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory hematological malignancies but is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). Early clinical recognition remains challenging, as the commonly used Immune Effector Cell-Associated Encephalopathy (ICE) score lacks sensitivity for subtle deficits.In this prospective bicentric study, 100 patients treated with CAR T-cells at Hannover Medical School and Charité - Universitätsmedizin Berlin underwent systematic neurological assessments using both ICE and the newly developed Berlin-Hannover ICANS Severity Assessment (BHISA). Examinations were performed at baseline prior to CAR T-cell infusion, on day 6-7 (±1 day) post-infusion, and during ICANS episodes. Data on the clinical course, other toxicities, comorbidities, CAR T-cell products, and ICANS treatment were collected.Thirty-seven patients (37
KW - BHISA (Other)
KW - CAR T-cell therapy (Other)
KW - ICANS (Other)
KW - ICE (Other)
KW - screening tools (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:41648666
C2 - pmc:PMC12867840
DO - DOI:10.3389/fneur.2026.1726779
UR - https://pub.dzne.de/record/285052
ER -